PDCD1 and neoplasm: Tumor cells evade immunosurveillance through the elevation of co-inhibitory/stimulatory PD-L1 or B7 ligands, which binds to inhibitory PD-1 or CTLA-4 receptors on T cells and resulted in the inhibition of anti-tumor immunity and exhaustion of T cells [41].